How GLOHBX redesigns incentives for innovation, access, and investment through outcome-linked finance.
In traditional price-pegged markets, the price of a medicine or service is anchored to what other countries pay.
While this appears to promote fairness, it often does the opposite: companies delay launching in lower-income markets to protect global price benchmarks.
Research shows the consequences clearly.
A study by Luca Maini (2020) found that external reference pricing accounted for over half of all drug-launch delays across 27 European countries—often extending access lags by 6–12 months in poorer markets.
A follow-up global analysis by Vokinger et al. (2023) revealed that reference-priced markets were 73 percent less likely to see a new medicine launched within nine months of approval.
In other words, price-peg logic slows innovation.
It rewards preservation of margins, not delivery of outcomes.
Value-proof financial markets—such as those GLOHBX enables—reverse this equation.
Here, value is earned through verified performance, not predetermined benchmarks.
Payments are tied to measurable outcomes—early diagnosis, treatment completion, or verified survival gains—validated through the C4 AI layer and transparent blockchain registries.
This means companies can launch early in frontier markets without risking global margins, because revenue is generated from performance-based bonds rather than fixed list prices.
From protection to performance. From delay to delivery.
GLOHBX makes early access investable.
